Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
Expert opinion on drug metabolism & toxicology • Vol. 7, Issue 4 • 2011
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Critical care medicine • Vol. 38, Issue 1 • 2010
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
Antimicrobial agents and chemotherapy • Vol. 48, Issue 9 • 2004
CD11/CD18 and CD14 share a common lipid A signaling pathway.
Journal of immunology (Baltimore, Md. : 1950) • Vol. 161, Issue 10 • 1998
